(内容请参阅英文版)
Neuroendocrine tumors (NETs), a rare cancer, lack accessible treatment options in many parts of Asia. While advanced radioligand therapy exists in Europe, its short radioactive half-life prevents widespread use in Asian markets. L'Ord'Invent is bridging this gap. The team is developing smarter, safer next-generation radioligands that precisely target cancer cells to minimise side effects and maximise quality of life. By establishing the first radiopharmaceutical capability in Hong Kong and the Greater Bay Area, the company is positioned to lead this high-growth market and deliver life-changing and epoch-making treatments to millions of patients.
Prof. Victor Lee
Clinical Professor
Department of Clinical Oncology
LKS Faculty of Medicine
Email: vhflee@hku.hk
- Gold Medal, International Exhibition of Inventions Geneva 2025
- Gold Medal, 10th International Invention Innovation Competition in Canada, iCAN 2025
- International Special Award, Turkish Inventors Association (TUMMIAD), iCAN 2025
- Organiser's Choice Awards, Selected by the Organizing Committee of iCAN 2025